| 13.11 -0.53 (-3.89%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.04 |
1-year : | 18.11 |
| Resists | First : | 13.73 |
Second : | 15.51 |
| Pivot price | 14.14 |
|||
| Supports | First : | 10.85 |
Second : | 9.03 |
| MAs | MA(5) : | 13.83 |
MA(20) : | 13.71  |
| MA(100) : | 13.51 |
MA(250) : | 12.11 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 44.4 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 17.14 | Low : | 6.43 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENTA ] has closed above bottom band by 0.8%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.77 - 13.87 | 13.87 - 13.94 |
| Low: | 12.85 - 12.98 | 12.98 - 13.08 |
| Close: | 12.94 - 13.11 | 13.11 - 13.24 |
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Mon, 29 Jun 2026
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sun, 28 Jun 2026
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 3000 Growth Benchmark - marketscreener.com
Thu, 25 Jun 2026
ENTA Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance
Thu, 28 May 2026
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
Wed, 13 May 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 92.7 (%) |
| Shares Short | 2,580 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -2.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | -89.6 % |
| Operating Margin | -69.1 % |
| Return on Assets (ttm) | -11.9 % |
| Return on Equity (ttm) | -59 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 2.37 |
| Sales Per Share | 2.37 |
| EBITDA (p.s.) | -1.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -5.05 |
| PEG Ratio | 0 |
| Price to Book value | 3.26 |
| Price to Sales | 5.5 |
| Price to Cash Flow | -48.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|